Open AccessHigh-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial
Author(s) -
Fiona Cresswell,
David B. Meya,
Enock Kagimu,
Daniel Grint,
Lindsey te Brake,
John Kasibante,
Emily Martyn,
Morris K Rutakingirwa,
Carson M Quinn,
Micheal Okirwoth,
Lillian Tugume,
Kenneth Ssembambulidde,
Abdu K Musubire,
Ananta S Bangdiwala,
Allan Buzibye,
Conrad Muzoora,
Elin M. Svensson,
Rob E. Aarnoutse,
David R. Boulware,
Alison M. Elliott
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab162
Subject(s) - medicine , rifampicin , interquartile range , dosing , cmax , pharmacokinetics , adverse effect , gastroenterology , confidence interval , randomized controlled trial , pharmacology , tuberculosis , pathology
High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human immunodeficiency virus (HIV) coinfection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess toxicity.